Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
21.48
+0.30 (1.42%)
At close: Dec 31, 2025, 4:00 PM EST
21.48
0.00 (0.00%)
After-hours: Dec 31, 2025, 7:58 PM EST
Immunome Employees
Immunome had 118 employees as of December 31, 2024. The number of employees increased by 63 or 114.55% compared to the previous year.
Employees
118
Change (1Y)
63
Growth (1Y)
114.55%
Revenue / Employee
$82,025
Profits / Employee
-$1,887,653
Market Cap
1.97B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMNM News
- 14 days ago - Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat - Seeking Alpha
- 15 days ago - Immunome Announces Pricing of Public Offering of Common Stock - Business Wire
- 16 days ago - Immunome Announces Proposed Public Offering of Common Stock - Business Wire
- 16 days ago - Immunome's experimental drug meets main goal in late-stage study - Reuters
- 16 days ago - Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire
- 17 days ago - Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire
- 27 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Immunome to Present at Upcoming Investor Conferences - Business Wire